Advanced Enzyme Technologies Ltd
Quarterly Earnings Release dated May 09, 2026
RESULTS
▲ Positive Development
LOW RISK
📅 Filed on BSE: 09 May 2026, 03:23 PM IST · BSE ID: f63ffe0c-3fa4-4b0e-a2b0-f4d7c6b3ddab
View Original BSE Filing (PDF)
💡
In Simple Terms
The company's quarterly profit increased by 69% compared to the same quarter last year, reaching INR 453 million.
🤖 AI Summary
- Consolidated Revenue from Operations for Q4 FY26 increased 22% YoY to INR 2,034 million.
- Consolidated EBITDA for Q4 FY26 grew 39% YoY to INR 632 million.
- Consolidated Profit After Tax (PAT) for Q4 FY26 rose 69% YoY to INR 453 million.
- Full year FY26 Consolidated Revenue reached INR 7,458 million, up 17% from FY25.
- Full year FY26 Consolidated PAT stood at INR 1,736 million, a 30% increase from FY25.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Consolidated Revenue Q4 FY26
INR 2,034 million
+22%
Consolidated EBITDA Q4 FY26
INR 632 million
+39%
Consolidated PAT Q4 FY26
INR 453 million
+69%
Consolidated EPS Q4 FY26
INR 3.84
+62%
Consolidated Revenue FY26
INR 7,458 million
+17%
Consolidated PAT FY26
INR 1,736 million
+30%
Human Nutrition Revenue Q4 FY26
INR 1,281 million
+24%
Domestic Sales Q4 FY26
INR 1,061 million
+51%
🏢 How This Affects the Company
Revenue growth was driven by the Human Nutrition segment, up 24% YoY, and Animal Nutrition, up 19% YoY. Domestic sales increased by 51% YoY in Q4 FY26, now accounting for 52% of total revenue.
Consolidated PAT margin expanded to 22% in Q4 FY26 from 16% in Q4 FY25. Financial costs decreased to INR 6 million in Q4 FY26 from INR 8 million in Q4 FY25.
The company plans to expand its B2C business in India with the new nutraceutical brand Wellfa. R&D investments are ongoing to expand application portfolios and strengthen the R&D team.
👥 What This Means For Shareholders
✅
Action Required
No action required based on this earnings release.
👤
Who Is Affected
All shareholders are affected by the improved financial performance, reflected in the 69% YoY increase in Q4 FY26 consolidated PAT to INR 453 million.
🔍
Management Signal
Management intends to expand the B2C business in India, strengthen R&D, and explore strategic acquisitions to enhance growth and market presence.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Q1 FY27 results — evaluate sustained growth in Human Nutrition segment.
Progress on Wellfa brand expansion in India for B2C market share.
Updates on new product launches in probiotics and biocatalysis development.
LOW RISK
No new specific risks identified; overall financial performance is positive.
💡 Investor Takeaway
Advanced Enzyme Technologies reported Q4 FY26 consolidated PAT up 69% YoY to INR 453 million, with revenue increasing 22% to INR 2,034 million. Full year FY26 consolidated PAT rose 30% to INR 1,736 million on 17% revenue growth to INR 7,458 million.
⚖️ Strengths & Concerns
✅ Positives
- Consolidated Profit After Tax (PAT) showed a significant 69% year-on-year growth in Q4 FY26, reaching INR 453 million.
- Domestic sales demonstrated robust growth of 51% year-on-year in Q4 FY26, contributing 52% of total revenue.
⚠️ Concerns
- International sales experienced a marginal increase of 1% YoY in Q4 FY26 to INR 973 million, with declines in Americas (-11%) and Europe (-7%).
- Bio-Processing segment showed a 10% sequential de-growth in Q4 FY26, falling to INR 324 million from INR 361 million in Q3 FY26.
📅 Company Track Record
Advanced Enzyme Technologies Ltd. filed audited financial results for Q4 and full year FY26 on May 09, 2026. The board also approved a final dividend of ₹1.35 and deferred an interim dividend for strategic capital.
Based on publicly available historical data. For context only.